Adult-onset Still's disease after ChAdOx1 nCoV-19 vaccine: a possible association

Laíssa Fiorotti Albertino; Isac Ribeiro Moulaz; Tammer Ferreira Zogheib; Martina Zanotti Carneiro Valentim; Ketty Lysie Libardi Lira Machado

doi:10.4322/acr.2021.403

Clinical Case Report

Adult-onset Still's disease after ChAdOx1 nCoV-19 vaccine: a possible association

Laíssa Fiorotti Albertino; Isac Ribeiro Moulaz; Tammer Ferreira Zogheib; Martina Zanotti Carneiro Valentim; Ketty Lysie Libardi Lira Machado

http://dx.doi.org/10.4322/acr.2021.403 Autops Case Rep, vol.12, e2021403, 2022

PDF

Downloads: 6

Abstract

With emergent Sars-Cov-2, a highly transmissive virus that caused millions of deaths worldwide, the development of vaccines became urgent to combat COVID-19. Although rare, important adverse effects had been described in a hypothetical scenario of immune system overstimulation or overreaction. Still’s disease is a rare inflammatory syndrome of unknown etiology. It manifests as a cytokine storm, mainly IL-18 and IL-1β, and presents itself with fever spikes, joint pain, maculopapular evanescent salmon-pink skin rash, and sore throat, among other symptoms. Here, we report a case of a 44-year-old healthy male who developed adult-onset Still’s disease (AOSD) with atypical symptoms after both doses of ChAdOx1 nCoV-19 vaccine with 3 months of dose interval. The medical team suspected Still's disease and started prednisone 1 mg/kg (40mg). The next day the patient showed a marked improvement in articular and chest pains and had no other fever episodes. Therefore, he was discharged to continue the treatment in outpatient care. On the six-month follow-up, the patient was free of complaints, and the progressive corticoid withdrawal plan was already finished.

Keywords

Adenovirus Vaccines, COVID-19 Vaccines, Still's Disease, Adult-Onset

References

1 Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155-62. http://dx.doi.org/10.1097/BOR.0000000000000776. PMid:33332890.

2 Sharabi A, Shiber S, Molad Y. Adult-onset Still’s disease following mRNA COVID-19 vaccination. Clin Immunol. 2021;233:108878. http://dx.doi.org/10.1016/j.clim.2021.108878. PMid:34763089.

3 Magliulo D, Narayan S, Ue F, Boulougoura A, Badlissi F. Adult-onset Still’s disease after mRNA COVID-19 vaccine. Lancet Rheumatol. 2021;3(10):e680-2. http://dx.doi.org/10.1016/S2665-9913(21)00219-8. PMid:34316726.

4 Leone F, Cerasuolo PG, Bosello SL, et al. Adult-onset Still’s disease following COVID-19 vaccination. Lancet Rheumatol. 2021;3(10):e678-80. http://dx.doi.org/10.1016/S2665-9913(21)00218-6. PMid:34316728.

5 Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Sève P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13(7):708-22. http://dx.doi.org/10.1016/j.autrev.2014.01.058. PMid:24657513.

6 Tomaras S, Goetzke CC, Kallinich T, Feist E. Adult-onset Still’s disease: clinical aspects and therapeutic approach. J Clin Med. 2021;10(4):733. http://dx.doi.org/10.3390/jcm10040733. PMid:33673234.

7 Kawasaki T, Ooka S, Mizushima M, et al. COVID-19 and adult-onset Still’s disease as part of hyperferritinemic syndromes. Mod Rheumatol Case Rep. 2022;6(1):101-5. http://dx.doi.org/10.1093/mrcr/rxab032. PMid:34592766.

8 Pascolini S, Vannini A, Deleonardi G, et al. COVID-19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci. 2021;14(2):502-8. http://dx.doi.org/10.1111/cts.12908. PMid:32989903.

9 Talotta R. COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases”. Clin Immunol. 2021;224:108665. http://dx.doi.org/10.1016/j.clim.2021.108665. PMid:33429060.

10 Getts MT, Miller SD. 99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: triggering of autoimmune diseases by infections. Clin Exp Immunol. 2010;160(1):15-21. http://dx.doi.org/10.1111/j.1365-2249.2010.04132.x. PMid:20415846.

11 Yoshioka K, Fujimoto S, Oba H, Minami M, Aoki T. Onset of adult-onset Still’s disease following influenza vaccination. Mod Rheumatol. 2011;21(4):432-5. http://dx.doi.org/10.3109/s10165-011-0418-7. PMid:21327453.

12 Sato T, Takeo N, Matsuda-Hirose H, Abe K, Nishida H, Hatano Y. Adult-onset Still’s disease following pneumococcal vaccination. Eur J Dermatol. 2021. In press. PMid:34427562.

13 Fujinami RS, von Herrath MG, Christen U, Whitton JL. Molecular mimicry, bystander activation or viral persistence: infections and autoimmune disease. Clin Microbiol Rev. 2006;19(1):80-94. http://dx.doi.org/10.1128/CMR.19.1.80-94.2006. PMid:16418524.

14 Stéphan JL, Zeller J, Hubert P, Herbelin C, Dayer JM, Prieur AM. Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol. 1993;11(4):451-6. PMid:8403593.

15 Christen U, Edelmann KH, McGavern DB, et al. A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes. J Clin Invest. 2004;114(9):1290-8. http://dx.doi.org/10.1172/JCI200422557. PMid:15520861.

16 Kim YJ, Koo BS, Kim YG, Lee CK, Yoo B. Clinical features and prognosis in 82 patients with adult-onset Still’s disease. Clin Exp Rheumatol. 2014;32(1):28-33. PMid:24050706.

Submitted date:
04/01/2022

Accepted date:
09/26/2022

Publication date:
11/07/2022

Adult-onset Still's disease after ChAdOx1 nCoV-19 vaccine: a possible association

Laíssa Fiorotti Albertino; Isac Ribeiro Moulaz; Tammer Ferreira Zogheib; Martina Zanotti Carneiro Valentim; Ketty Lysie Libardi Lira Machado

Abstract

Keywords

References

Links

Share

Autops Case Rep